Evidence map›Paper›PMID 33856664›Full record

ArticleInternal and emergency medicine2021

High-dose steroids for the treatment of severe COVID-19.

Matteo Piccica, Filippo Lagi, Michele Trotta, Michele Spinicci, Lorenzo Zammarchi, Alessandro Bartoloni, COCORA Working Group

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. New onset diabetes mellitus in post-COVID-19 patients.Journal of family medicine and primary care · 2022
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Matteo PiccicaDepartment of Experimental and Clinical Medicine, SOD Malattie Infettive eTropicali, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Filippo LagiDepartment of Experimental and Clinical Medicine, SOD Malattie Infettive eTropicali, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Michele TrottaInfectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Michele SpinicciDepartment of Experimental and Clinical Medicine, SOD Malattie Infettive eTropicali, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. michele.spinicci@unifi.it.ORCID 0000-0002-5377-7118
Lorenzo ZammarchiDepartment of Experimental and Clinical Medicine, SOD Malattie Infettive eTropicali, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Alessandro BartoloniDepartment of Experimental and Clinical Medicine, SOD Malattie Infettive eTropicali, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
COCORA Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentAgedAged, 80 and overFemaleGlucocorticoidsHumansItalyMaleMethylprednisoloneMiddle AgedPatient AcuityGlucocorticoidsMethylprednisolone

Identifiers

PMID33856664
PMCPMC8047517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.